Take our post-test to claim CME credits.
To read a companion newsletter click here.
Selecting the most appropriate Disease Modifying Therapy (DMT) is becoming more complicated for patients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/risk equation, and making the question of which treatment is most appropriate for which patient more difficult to answer.
That’s the focus of our discussion with Dr. Erin Longbrake, Assistant Professor of Neurology and Director of the Multiple Sclerosis Fellowship Program at Yale University, in this eMultipleSclerosis Review podcast.
Podcast (emultiplesclerosis): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS